Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options



The FDA has approved two targeted therapies, osimertinib (Tagrisso™) and necitumumab (Portrazza™), for the treatment of some patients with advanced lung cancer.



Source link

Comments are closed.